358 related articles for article (PubMed ID: 18551073)
1. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
2. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
3. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
Zarkhin V; Li L; Sarwal MM
Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
[No Abstract] [Full Text] [Related]
4. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.
Thaunat O; Patey N; Caligiuri G; Gautreau C; Mamani-Matsuda M; Mekki Y; Dieu-Nosjean MC; Eberl G; Ecochard R; Michel JB; Graff-Dubois S; Nicoletti A
J Immunol; 2010 Jul; 185(1):717-28. PubMed ID: 20525884
[TBL] [Abstract][Full Text] [Related]
5. Treatment of vascular rejection with rituximab in cardiac transplantation.
Garrett HE; Duvall-Seaman D; Helsley B; Groshart K
J Heart Lung Transplant; 2005 Sep; 24(9):1337-42. PubMed ID: 16143254
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
7. Drug insight: rituximab in renal disease and transplantation.
Salama AD; Pusey CD
Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
9. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.
Di Carlo E; D'Antuono T; Pompa P; Giuliani R; Rosini S; Stuppia L; Musiani P; Sorrentino C
Clin Cancer Res; 2009 May; 15(9):2979-87. PubMed ID: 19366834
[TBL] [Abstract][Full Text] [Related]
10. [Lymphoid neogenesis and lymphangiogenesis: two newcomers in the pathophysiology of chronic rejection].
Attuil-Audenis V; Duthey A; Patey N; Gautreau C; McGregor B; Morelon E; Michel JB; Nicoletti A; Thaunat O
Nephrol Ther; 2009 Apr; 5(2):91-6. PubMed ID: 18678539
[TBL] [Abstract][Full Text] [Related]
11. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
12. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection.
Pescovitz MD
Clin Transplant; 2006; 20(1):48-54. PubMed ID: 16556153
[TBL] [Abstract][Full Text] [Related]
13. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
15. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
16. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
17. High expression of TIAF-1 in chronic kidney and liver allograft rejection and in activated T-helper cells.
van der Leij J; van den Berg A; Albrecht EW; Blokzijl T; Roozendaal R; Gouw AS; de Jong KP; Stegeman CA; van Goor H; Chang NS; Poppema S
Transplantation; 2003 Jun; 75(12):2076-82. PubMed ID: 12829915
[TBL] [Abstract][Full Text] [Related]
18. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
19. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response.
Thaunat O; Field AC; Dai J; Louedec L; Patey N; Bloch MF; Mandet C; Belair MF; Bruneval P; Meilhac O; Bellon B; Joly E; Michel JB; Nicoletti A
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14723-8. PubMed ID: 16192350
[TBL] [Abstract][Full Text] [Related]
20. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]